Towa Pharmaceutical Co., Ltd. (4553)

Name: Towa Pharmaceutical Co., Ltd. (4553) — storico dei bilanci
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Storico di ricavi, utili e flussi di cassa dai bilanci ufficiali.

Healthcare · Wall Street (USA) · Ultimo aggiornamento: 2026-10-02

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. The company operates through two segments; Domestic and Overseas. It provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from tablets, capsules, injectable, patches, eye drops, and other products. The company also offers IT service related to healthcare; disease risk testing services; and sale of quasi drugs.

Dati chiave

Capitalizzazione di mercato: JPY 172 billion
Ricavi (esercizio chiuso a 2026-03-31): JPY 273.7B
Utile netto: JPY 5.2B
Margine lordo: 36.2%
Margine netto: 1.9%

Vedi grafici interattivi e bilanci completi → Modello di valutazione (DCF) →

Conto economico annuale

Conto economico	2026-03-31	2025-03-31	2024-03-31	2023-03-31
Entrate totali	JPY 273.7B	JPY 259.6B	JPY 227.9B	JPY 208.9B
Utile lordo	JPY 99.1B	JPY 94.7B	JPY 81.4B	JPY 72.7B
Risultato Operativo (EBIT)	JPY 23.1B	JPY 23.2B	JPY 17.6B	JPY 5.5B
Reddito netto	JPY 5.2B	JPY 19.0B	JPY 16.2B	JPY 2.2B

Fonte: bilanci pubblici della società (SEC). Verificare su SEC EDGAR prima di fare affidamento su qualsiasi cifra.

Stati patrimoniali, flussi di cassa, dati trimestrali e indici completi nel visualizzatore interattivo di 4553. /companies/us/4553

Aziende simili

4887 · Sawai Group Holdings Co., Ltd.

Le informazioni di questo sito sono solo a scopo educativo e informativo; non costituiscono consulenza finanziaria. Non vengono pubblicati prezzi obiettivo né raccomandazioni.

English version →Tutte le azioni

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.